Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(15%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
5
38%
Ph phase_1
4
31%
Ph phase_3
4
31%

Phase Distribution

4

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
4(30.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(4)
Completed(9)

Detailed Status

Completed9
Not yet recruiting2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (30.8%)
Phase 25 (38.5%)
Phase 34 (30.8%)

Trials by Status

not_yet_recruiting215%
completed969%
recruiting18%
active_not_recruiting18%

Recent Activity

2 active trials
Showing 5 of 13
completedphase_3

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

NCT06649344
completedphase_3

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

NCT06650007
not_yet_recruitingphase_2

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

NCT07660848
recruitingphase_1

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

NCT07540754
completedphase_2

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

NCT06054698
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06649344Phase 3

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Completed
NCT06650007Phase 3

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

Completed
NCT07660848Phase 2

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

Not Yet Recruiting
NCT07540754Phase 1

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

Recruiting
NCT06054698Phase 2

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Completed
NCT06762600Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

Completed
NCT07285902Phase 3

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Active Not Recruiting
NCT06396429Phase 3

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Completed
NCT06792955Phase 1

The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution

Completed
NCT05966272Phase 2

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Completed
NCT05881837Phase 2

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Completed
NCT06654960Phase 1

Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects

Completed
NCT06565871Phase 2

A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea

Not Yet Recruiting

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13